1. Improved Overall Survival after Contralateral Risk-Reducing Mastectomy in Brca1/2 Mutation Carriers with a History of Unilateral Breast Cancer: A Prospective Analysis
- Author
-
Heemskerk-Gerritsen, B.A.M., Rookus, M.A., Aalfs, C.M., Ausems, M.G.E.M., Collee, J.M., Jansen, L., Kets, C.M., Keymeulen, K.B.M.I., Koppert, L.B., Meijers-Heijboer, H.E.J., Mooij, T.M., Tollenaar, R.A.E.M., Vasen, H.F.A., Hooning, M.J., Seynaeve, C., HEBON, Human Genetics, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), MUMC+: MA Heelkunde (9), RS: GROW - Oncology, RS: GROW - R4 - Reproductive and Perinatal Medicine, Human genetics, CCA - Oncogenesis, Medical Oncology, Clinical Genetics, and Surgery
- Subjects
Oncology ,Cancer Research ,SURGERY ,medicine.medical_treatment ,Genes, BRCA2 ,Genes, BRCA1 ,FAMILIES ,prevention ,contralateral risk-reducing mastectomy ,Prospective Studies ,Non-U.S. Gov't ,PREDICTORS ,skin and connective tissue diseases ,Mastectomy ,Aged, 80 and over ,Medicine(all) ,OUTCOMES ,Research Support, Non-U.S. Gov't ,Hazard ratio ,PROPHYLACTIC MASTECTOMY ,WOMEN ,GERMLINE MUTATIONS ,Middle Aged ,Multicenter Study ,Cohort ,Female ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,Adult ,medicine.medical_specialty ,Breast Neoplasms ,Research Support ,survival ,OVARIAN-CANCER ,breast cancer ,Breast cancer ,SDG 3 - Good Health and Well-being ,Internal medicine ,Journal Article ,medicine ,Humans ,Aged ,Proportional hazards model ,business.industry ,MORTALITY ,Prophylactic Mastectomy ,BRCA1 ,EFFICACY ,medicine.disease ,Confidence interval ,Surgery ,Mutation ,Ovarian cancer ,business - Abstract
Data on survival of BRCA1/2-associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk-reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA-associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time-dependent covariate. The median follow-up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (p
- Published
- 2014
- Full Text
- View/download PDF